Key Findings

•Eliquis is currently the top choice for stroke prevention in NVAF, being used in 56% of patients, followed by Xarelto at 26%

• Mirroring usage, 77% of cardiologists perceive Eliquis as performing “extremely well”, while only 47% have equally positive perceptions of Xarelto

• Eliquis’ twice daily dosing is considered its only major drawback, while safety & efficacy-related unmet needs are noted for Xarelto

Future Perspectives: Awareness of FXIa inhibitors on the horizon are modest, with some aware of early clinical setbacks.

• Only 50% of cardiologists are aware of in-development FXIa inhibitors, with asundexian, abelacimab and milvexian being the top 3 recalled pipeline therapies

• 40% of cardiologists are both aware and familiar with asundexian’s latest clinical data, and most of those (6 out of 10) are specifically aware of the halting of OCEANIC-AF due to inferior data vs Eliquis C.

Enter your information below to instantly access the full white paper:

ZoomRx Blog - Omnichannel myths WP

ZoomRx uses the info you provide to fulfill your request and contact you about relevant insights, products, and services. You may unsubscribe from all communications at any time. For more information, view our full privacy policy